Otsuka’s 2016 Earnings Falter as Abilify Sales Dive 70%

February 15, 2017
Otsuka Holdings suffered bleak earnings in 2016 as global sales of its bread-and-butter antipsychotic Abilify (aripiprazole) tumbled over 70% due to its patent expiration in the US and Europe, and a big price cut in Japan. The Japanese company said...read more